Who are Teriparatide (PF708)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Yorvipath, PTH/Calcium, TERIPARATIDE, Teriparatide (rDNA origin), FORSTEO, Teriparatide Pen Injector.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teriparatide-pf708.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Teriparatide (PF708) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teriparatide (PF708) (Teriparatide (PF708)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parathyroid hormone analog. Area: Endocrinology.

phase 3 Parathyroid hormone analog PTH1R Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Teriparatide (PF708) (Teriparatide (PF708)) — Pfenex, Inc. Teriparatide is a recombinant form of parathyroid hormone used to treat osteoporosis by stimulating bone growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Teriparatide (PF708) TARGET	Teriparatide (PF708)	Pfenex, Inc	phase 3	Parathyroid hormone analog	PTH1R
Yorvipath	PALOPEGTERIPARATIDE	Ascendis Pharma Bone	marketed		parathyroid hormone 1 receptor (PTH1R)	2025-01-01
PTH/Calcium	PTH/Calcium	Shire	phase 3	Hormone replacement / Mineral supplement combination	PTH receptor (PTH1R)
TERIPARATIDE	TERIPARATIDE		marketed	Parathyroid Hormone Analog [EPC]		2002-01-01
Teriparatide (rDNA origin)	Teriparatide (rDNA origin)	Bio Sidus SA	marketed	Parathyroid hormone analog	PTH1 receptor (PTHR1)
FORSTEO	FORSTEO	Shenzhen Salubris Pharmaceuticals Co., Ltd.	marketed	Parathyroid hormone analog	PTH1 receptor
Teriparatide Pen Injector	Teriparatide Pen Injector	University of Edinburgh	marketed	Parathyroid hormone analog	PTH1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parathyroid hormone analog class)

Bio Sidus SA · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Pfenex, Inc · 1 drug in this class
Shenzhen Salubris Pharmaceuticals Co., Ltd. · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teriparatide (PF708) — Competitive Intelligence Brief. https://druglandscape.com/ci/teriparatide-pf708. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab